Anti-#-synuclein, clone 1D22 ZooMAb�Rb

Application

Anti-a-synuclein, clone 1D22 ZooMAb, Cat. No. ZRB1134, is a recombinant Rabbit monoclonal antibody that specifically targets a-synuclein and has been tested for use in Affinity Binding Assay, Immunohistochemistry (Paraffin), and Western Blotting.

Quality Control TestingWestern Blotting Analysis: A 1:1,000 dilution of this antibody detected a-synuclein in rat brain tissue lysate.Tested applicationsWestern Blotting Analysis: A 1:1,000 dilution from a representative lot detected a-synuclein in human and mouse brain tissue lysate.Affinity Binding Assay: A representative lot of this antibody bound a-synuclein peptide with a KD of 7.5 x 10-10 in an affinity binding assay.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected a-synuclein in human cerebral cortex tissue sections.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

KLH-conjugated linear peptide corresponding to 21 amino acids from the C-terminal region of human a-synuclein.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

30 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 1D22 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects a-synuclein. It targets an epitope within 21 amino acids from the C-terminal region.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

a-synuclein (UniProt: P37840; also known as Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, NACP) is encoded by the SNCA (also known as NACP; PARK1) gene (Gene ID: 6622) in human. a-synuclein is abundantly expressed in the brain and is found in a classic amyloid fibril form within the intra-neuronal Lewy body deposits of Parkinson′s disease brains. In its monomeric form it participates in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores. It acts by increasing local Ca2+ release from microdomains which is essential for the enhancement of ATP-induced exocytosis. In its multimeric form it acts as a molecular chaperone assisting in the folding of synaptic fusion components called SNAREs at presynaptic membrane. It is also involved in the regulation of dopamine release and transport. It is also reported to reduce neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation. Post-translationally it can be phosphorylated, predominantly on serine residues. Phosphorylation of serine 129 is reported to be selective and extensive in synucleinopathy lesions. Genetic alterations of SNCA gene is reported to result in aberrant polymerization into fibrils, which is associated with several neurodegenerative diseases (synucleinopathies). Mutations in SNCA gene are also known to Parkinson′s disease characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. The pathology of Parkinson s disease involves progressive loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies in surviving neurons in various areas of the brain. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.